Search research articles
Contact Us
Filters
Showing results (1-10 of 14) with videos related to
Page
of 2
Sort By:
American Journal of Clinical Pathology
|
June 21, 2011
The knowns and the unknowns in HER2 testing in breast cancer
Allen M Gown, Lynn C Goldstein
Cancer Management and Research
|
December 29, 2010
Positive response to neoadjuvant cyclophosphamide and doxorubicin in topoisomerase II nonamplified/HER2/neu negative/polysomy 17 absent breast cancer patients
Henry G Kaplan, Judith A Malmgren, Mary Atwood, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 12, 2012
Concordance between human epidermal growth factor receptor 2 testing by reverse transcriptase polymerase chain reaction and fluorescent in situ hybridization
Allen M Gown, Lynn C Goldstein, Harry C Hwang, et al.
American Journal of Physiology. Endocrinology and Metabolism
|
June 6, 2013
One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice
Kathryn Aston-Mourney, Shoba L Subramanian, Sakeneh Zraika, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 28, 2011
Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy
Chun Hing Tse, Harry C Hwang, Lynn C Goldstein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 11, 2010
Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories
Frederick L Baehner, Ninah Achacoso, Tara Maddala, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
May 20, 2008
High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system
Allen M Gown, Lynn C Goldstein, Todd S Barry, et al.
JAMA
|
April 29, 2004
HER-2 testing in breast cancer using parallel tissue-based methods
Hadi Yaziji, Lynn C Goldstein, Todd S Barry, et al.
Breast Cancer Research and Treatment
|
January 19, 2008
HER2 in well differentiated breast cancer: is testing necessary?
G Kenneth Haines, Elizabeth Wiley, Barbara Susnik, et al.
The American Journal of Surgical Pathology
|
December 2, 2009
Relationship between clinical and pathologic features of ductal carcinoma in situ and patient age: an analysis of 657 patients
Laura C Collins, Ninah Achacoso, Larissa Nekhlyudov, et al.
Page
of 2
Search research articles
Search
Showing results (1-10 of 14) with videos related to
Sort By:
Page
of 2
American Journal of Clinical Pathology
|
June 21, 2011
The knowns and the unknowns in HER2 testing in breast cancer
Allen M Gown, Lynn C Goldstein
Cancer Management and Research
|
December 29, 2010
Positive response to neoadjuvant cyclophosphamide and doxorubicin in topoisomerase II nonamplified/HER2/neu negative/polysomy 17 absent breast cancer patients
Henry G Kaplan, Judith A Malmgren, Mary Atwood, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
April 12, 2012
Concordance between human epidermal growth factor receptor 2 testing by reverse transcriptase polymerase chain reaction and fluorescent in situ hybridization
Allen M Gown, Lynn C Goldstein, Harry C Hwang, et al.
American Journal of Physiology. Endocrinology and Metabolism
|
June 6, 2013
One year of sitagliptin treatment protects against islet amyloid-associated β-cell loss and does not induce pancreatitis or pancreatic neoplasia in mice
Kathryn Aston-Mourney, Shoba L Subramanian, Sakeneh Zraika, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
September 28, 2011
Determining true HER2 gene status in breast cancers with polysomy by using alternative chromosome 17 reference genes: implications for anti-HER2 targeted therapy
Chun Hing Tse, Harry C Hwang, Lynn C Goldstein, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
August 11, 2010
Human epidermal growth factor receptor 2 assessment in a case-control study: comparison of fluorescence in situ hybridization and quantitative reverse transcription polymerase chain reaction performed by central laboratories
Frederick L Baehner, Ninah Achacoso, Tara Maddala, et al.
Modern Pathology : an Official Journal of the United States and Canadian Academy of Pathology, Inc
|
May 20, 2008
High concordance between immunohistochemistry and fluorescence in situ hybridization testing for HER2 status in breast cancer requires a normalized IHC scoring system
Allen M Gown, Lynn C Goldstein, Todd S Barry, et al.
JAMA
|
April 29, 2004
HER-2 testing in breast cancer using parallel tissue-based methods
Hadi Yaziji, Lynn C Goldstein, Todd S Barry, et al.
Breast Cancer Research and Treatment
|
January 19, 2008
HER2 in well differentiated breast cancer: is testing necessary?
G Kenneth Haines, Elizabeth Wiley, Barbara Susnik, et al.
The American Journal of Surgical Pathology
|
December 2, 2009
Relationship between clinical and pathologic features of ductal carcinoma in situ and patient age: an analysis of 657 patients
Laura C Collins, Ninah Achacoso, Larissa Nekhlyudov, et al.
Page
of 2